Halozyme’s Phase II Study In Advanced Pancreas Cancer Meets Endpoints

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Halozyme Therapeutics Inc. reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its HALO 202 study, a phase II randomized, multi-center clinical trial of lead investigational drug PEGPH20 in combination with ABRAXANE(nab-paclitaxel) and gemcitabine in stage IV pancreas cancer patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login